[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

[HTML][HTML] Structural understanding of SARS-CoV-2 virus entry to host cells

K Le, S Kannappan, T Kim, JH Lee, HR Lee… - Frontiers in Molecular …, 2023 - frontiersin.org
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a major global health concern associated with millions of …

[HTML][HTML] Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients

R Rouet, JY Henry, MD Johansen, M Sobti… - Nature …, 2023 - nature.com
Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-
2 monoclonal antibodies and vaccines currently used in clinical practice; broadly …

[HTML][HTML] The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA. 2.86

D Zhou, P Supasa, C Liu, A Dijokaite-Guraliuc… - Nature …, 2024 - nature.com
Under pressure from neutralising antibodies induced by vaccination or infection the SARS-
CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all …

[HTML][HTML] Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing …

MS Piepenbrink, JG Park, A Deshpande, A Loos… - PLoS …, 2022 - journals.plos.org
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) marks the third novel β-
coronavirus to cause significant human mortality in the last two decades. Although vaccines …

[HTML][HTML] A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection

LJ Adams, LA VanBlargan, Z Liu, P Gilchuk, H Zhao… - Cell Reports …, 2023 - cell.com
Most neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAbs) target the receptor
binding domain (RBD) of the spike (S) protein. Here, we characterize a panel of mAbs …

[HTML][HTML] A structure-function analysis shows SARS-CoV-2 BA. 2.86 balances antibody escape and ACE2 affinity

C Liu, D Zhou, A Dijokaite-Guraliuc, P Supasa… - Cell Reports …, 2024 - cell.com
Summary BA. 2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains
many mutations in the spike gene. It appears to have originated from BA. 2 and is distinct …

[HTML][HTML] Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes

J Hurtado, TF Rogers, DB Jaffe, BA Adams, S Bangaru… - Cell Reports, 2024 - cell.com
The development of vaccines and therapeutics that are broadly effective against known and
emergent coronaviruses is an urgent priority. We screened the circulating B cell repertoires …

[HTML][HTML] Exploring Factors Influencing Changes in Incidence and Severity of Multisystem Inflammatory Syndrome in Children

P Castaldo, G d'Alanno, GB Biserni, M Moratti, F Conti… - Pathogens, 2023 - mdpi.com
Multisystem inflammatory syndrome (MIS-C) is a rare condition associated with COVID-19
affecting children, characterized by severe and aberrant systemic inflammation leading to …

[HTML][HTML] Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 …

G Verkhivker, M Alshahrani, G Gupta - International Journal of Molecular …, 2023 - mdpi.com
Evolutionary and functional studies have suggested that the emergence of Omicron variants
can be determined by multiple fitness tradeoffs including immune escape, binding affinity …